What's New

July

Kerri Zavota, DVM; Decision and Order (PDF) (July 28, 2026)

Gene M. Koop, D.D.S.; Decision and Order (PDF) (July 28, 2026)

60-Day Notice: U.S. Official Order Forms for Schedules I and II Controlled Substances DEA Form 222 (PDF) (July 23, 2026)

60-Day Notice: Recordkeeping for the Transfer of Electronic Prescriptions in Schedules III-V between Pharmacies (PDF) (July 23, 2026)

60-Day Notice: Recordkeeping for Partial fills of Prescriptions (PDF) (July 23, 2026)

American Radiolabeled Chem (PDF) (July 23, 2026)

Cerilliant Corporation (PDF) (July 22, 2026)

Catalent Greenville, Inc. (PDF) (July 16, 2026)

AMPAC Fine Chemicals LLC (PDF) (July 16, 2026)

Unither Manufacturing LLC (PDF) (July 16, 2026)

Catalent CTS, LLC (PDF) (July 16, 2026)

Barlow St-Clair Lynch, M.D.; Decision and Order (PDF) (July 14, 2026)

David Enright, M.D.; Decision and Order (PDF) (July 14, 2026)

Shane Lydon, M.D.; Decision and Order (PDF) (July 14, 2026)

Frederick Tanzer, M.D.; Decision and Order (PDF) (July 10, 2026)

Timothy Genetta, D.O.; Decision and Order (PDF) (July 10, 2026)

Mark Allen, D.D.S.; Decision and Order (PDF) (July 10, 2026)

Ruth Jones, D.O.; Decision and Order (PDF) (July 10, 2026)

Mariana Moualem, F.N.P.; Decision and Order (PDF) (July 10, 2026)

Proposed Rule: Designation of Phenethyl Halides as List I Chemicals (PDF) (July 9, 2026)

Proposed Rule: Placement of Tianeptine in Schedule I (PDF) (July 8, 2026)

Benuvia Operations, LLC (PDF) (July 7, 2026)

Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I (PDF) (July 6, 2026)

Temporary Placement of 7-Hydroxymitragynine Above a Specified Threshold in Schedule I (PDF) (July 6, 2026)

Proposed Amendment: Temporary Placement of 5,6-Dichloro Brorphine, 5,6-Dichloro Desmethylchlorphine, N-Propionitrile Chlorphine, and Spirochlorphine in Schedule I of the Controlled Substances Act (PDF) (July 1, 2026)

April

Final Rule: Rescheduling of Food and Drug Administration Approved Products Containing Marijuana From Schedule I to Schedule III; Corresponding Change to Permit Requirements (PDF) (April 28, 2026)

Proposed Rulemaking: Rescheduling of Marijuana (PDF) (April 28, 2026)

Proposed Rulemaking; Withdrawal: Rescheduling of Marijuana; Withdrawal (PDF) (April 28, 2026)

Final Rule: Placement of MDMB-4en-PINACA in Schedule I (PDF) (April 24, 2026)

AJNA Biosciences (PDF) (April 21, 2026)

VA Cooperative Studies Program (PDF) (April 21, 2026)

Leading Pharma LLC (PDF) (April 21, 2026)

60-Day Notice: Drug Use Statement (PDF) (April 17, 2026)

Usona Institute, Inc. (PDF) (April 17, 2026)

Quagen Pharmaceuticals LLC (PDF) (April 17, 2026)

LTS Therapy Systems, LLC (PDF) (April 17, 2026)

Royal Emerald Pharmaceuticals (PDF) (April 17, 2026)

30-Day Notice: Title—Registration for Controlled Substances Act Data-Use Request (PDF) (April 13, 2026)

Final Rule: Designation of P2P Methyl Glycidic Acid as a List I Chemical (PDF) (April 3, 2026)

Blue Rabbit Veterinary LLC (PDF) (April 3, 2026)

Lipomed/LGC Standards (PDF) (April 3, 2026)

Purisys, LLC (PDF) (April 3, 2026)

Research Triangle Institute (PDF) (April 3, 2026)

Indivior Manufacturing LLC (PDF) (April 1, 2026)

Research Triangle Institute (PDF) (April 1, 2026)

Pharmaron Manufacturing Services (US) LLC (PDF) (April 1, 2026)

Royal Emerald Pharmaceuticals (PDF) (April 1, 2026)

Fisher Clinical Services, Inc. (PDF) (April 1, 2026)

Sterling Wisconsin, LLC (PDF) (April 1, 2026)

Fisher Clinical Services, Inc. (PDF) (April 1, 2026)

March

Chemtos, LLC (PDF) (March 30, 2026)

Usona Institute (PDF) (March 30, 2026)

Pharmaron Manufacturing Services (US) LLC (PDF) (March 30, 2026)

SpecGx LLC (PDF) (March 26, 2026)

Final Rule: Placement of 3-Methoxyphencyclidine (1-(1-(3-Methoxyphenyl)cyclohexyl)piperidine) in Schedule I (PDF) (March 23, 2026)

Exempt Chemical Preparations Under the Controlled Substances Act (PDF) (March 20, 2026)

Ordering Schedule I and II Controlled Substances Using DEA Form 222; Technical Amendments (PDF) (March 20, 2026)

Siegfried Grafton, Inc. (PDF) (March 19, 2026)

SpecGx LLC (PDF) (March 19, 2026)

Patheon API Services, Inc. (PDF) (March 19, 2026)

Siegfried Grafton, Inc. (PDF) (March 19, 2026)

United States Pharmacopeial Convention (PDF) (March 19, 2026)

Sterling Wisconsin, LLC (PDF) (March 19, 2026)

Pisgah Laboratories Inc. (PDF) (March 19, 2026)

Temporary Placement of Bromazolam in Schedule I (PDF) (March 16, 2026)

Purisys, LLC (PDF) (March 13, 2026)

Pisgah Laboratories Inc. (PDF) (March 13, 2026)

Stepan Company (PDF) (March 13, 2026)

Lonza Tampa, LLC (PDF) (March 13, 2026)

Patheon API Services Inc. (PDF) (March 13, 2026)

Final Rule: Designation of Propionyl Chloride as a List I Chemical (PDF) (March 10, 2026)

Sigma Aldrich Research Biochemicals Inc. (PDF) (March 10, 2026)

Stepan Company (PDF) (March 4, 2026)

Catalent Greenville, Inc. (PDF) (March 4, 2026)

Amneal Pharmaceuticals, LLC (PDF) (March 4, 2026)

Parexel International, LLC (PDF) (March 4, 2026)

Restek Corporation (PDF) (March 4, 2026)

Maridose LLC (PDF) (March 4, 2026)

Patheon API Inc. (PDF) (March 4, 2026)

Restek Corporation (PDF) (March 4, 2026)

Final Rule: Placement of Clonazolam, Diclazepam, Etizolam, Flualprazolam, and Flubromazolam in Schedule I of the Controlled Substances Act (PDF) (March 2, 2026)

 

  • REGISTRATION
  • REPORTING
  • RESOURCES
  • CONTACT US
  • PRIVACY NOTICE
  • GET EMAIL UPDATES